LIPELLA PHARMACEUTICALS, INC.

Basic Information

5414 GUARINO RD
PITTSBURGH, PA, 15217-1919

Company Profile

n/a

Additional Details

Field Value
DUNS: 187190850
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation

    Amount: $224,999.00

    DESCRIPTION provided by applicant This project entails the development of a novel dual component MRI contrast agent formulation for the detecting permeability in the luminal surface of the urinary ...

    STTR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Preclinical Development of Tacrolimus for Radiation Cystitis

    Amount: $648,461.00

    DESCRIPTION provided by applicant This project entitied andquot Preclinical Development of Tracrolimus for Radiation Cystitisandquot will fund key experiments to advance the commercial developmen ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Preclinical Development of Tacrolimus for Radiation Cystitis

    Amount: $222,176.00

    DESCRIPTION (provided by applicant): This project, entitied Preclinical Development of Tracrolimus for Radiation Cystitis will fund key experiments to advance the commercial development of LP-10. LP ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $741,288.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. L ...

    STTR Phase II 2014 Department of Health and Human Services
  5. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $741,288.00

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions L ...

    STTR Phase II 2014 Department of Health and Human Services National Institutes of Health
  6. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $999,282.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposom ...

    SBIR Phase II 2011 Department of Health and Human Services
  7. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SB ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $740,688.00

    DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder sy ...

    STTR Phase I 2009 Department of Health and Human Services
  9. Intravesical Liposome Treatment for Interstitial Cystitis

    Amount: $750,000.00

    DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladd ...

    SBIR Phase II 2008 Department of Health and Human Services
  10. Intravesical Liposome Treatment for Interstitial Cystitis

    Amount: $99,617.00

    DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladd ...

    SBIR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government